Orthopilot Elite Post-Market Clinical Follow-Up
Launched by AESCULAP AG · Jan 23, 2019
Trial Information
Current as of May 17, 2025
Completed
Keywords
ClinConnect Summary
The study is designed as a prospective, non-interventional, multicenter, comparative cohort study. The product under investigation will be used in routine clinical practice and according to the authorized Instructions for Use (IfU). Those data that are obtained in routine clinical use will be documented in the Case Report Form (CRF).
The study design is based on a two-arms design. The patients for the both groups will be recruited consecutively, starting with group A. The study will prove the equivalence of the groups regarding the outcome of the postoperative lower limb alignment (mechani...
Gender
ALL
Eligibility criteria
- Inclusion: Inclusion Criteria:
- • Patients with indication for Total Knee Arthroplasty using the Aesculap OrthoPilot® navigation system and a corresponding primary implant
- • Dated and signed informed consent
- • Exclusion: Exclusion Criteria
- • Pregnancy
- • Patients \< 18 years
- • Patients unable to participate at the follow-up examination (physically, mentally)
- • Previous joint replacement at the indexed knee
About Aesculap Ag
Aesculap AG is a prominent global medical device manufacturer specializing in surgical instruments, implants, and innovative healthcare solutions. With a rich history rooted in excellence and innovation, Aesculap AG is dedicated to advancing surgical practices through cutting-edge technology and a commitment to improving patient outcomes. The company collaborates with healthcare professionals and institutions to conduct clinical trials that evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of quality and performance. Through its rigorous research and development initiatives, Aesculap AG aims to contribute significantly to the field of medicine and enhance the standards of surgical care worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dresden, , Germany
Freiburg, , Germany
Hamburg, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials